Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Implications for Systemic Therapy in Breast Cancer

March 29th 2019

Novel Therapies in TNBC: Real-World Experience

March 29th 2019

I-O + PARP Inhibition for Triple-Negative Breast Cancer

March 29th 2019

Checkpoint Inhibitors for Triple-Negative Breast Cancer

March 29th 2019

Adjuvant T-DM1 Therapy in HER2+ Breast Cancer

March 29th 2019

Neoadjuvant Therapy in HER2+ Breast Cancer

March 29th 2019

Adjuvant Therapy for HR+ Breast Cancer

March 29th 2019

Genomic Testing & Adjuvant Therapy in HR+ Breast Cancer

March 29th 2019

CDK4/6 Inhibitors: Treating Beyond Progression

March 29th 2019

Selecting a CDK4/6 Inhibitor in HR+ Breast Cancer

March 29th 2019

Managing CDK4/6 Inhibitor Adverse Events

March 29th 2019

CDK4/6 Inhibitor Toxicity in HR+ Breast Cancer

March 29th 2019

CDK4/6 Inhibitors for HR+ Breast Cancer

March 29th 2019

Fulvestrant/Anastrozole Combo Improves Survival in Metastatic HR+ Breast Cancer

March 29th 2019

The frontline combination of fulvestrant and anastrozole resulted in a sustained benefit in progression-free survival and a significant improvement in overall survival compared with anastrozole alone in patients with postmenopausal, HR–positive metastatic breast cancer, according to long-term results of the SWOG S0226 trial.

Promising Findings Pave Way for Patients With TNBC

March 28th 2019

Although it has been difficult to identify a specific target for triple-negative breast cancer, several therapeutic classes are showing great promise.

Dr. Euhus on the Rarity of Angiosarcoma of the Breast

March 28th 2019

David M. Euhus, MD, director of breast surgery, professor of surgery, Johns Hopkins Medicine, discusses the rarity of angiosarcoma of the breast.

FDA Proposes Policy Changes to Improve Mammography Quality Standards

March 28th 2019

The FDA has proposed amendments to key policies to modernize breast cancer screening and improve mammography services, in order to enable healthcare providers and patients to make more informed medical decisions

Progress Continues in HR+/HER2- Breast Cancer Paradigm

March 26th 2019

Kristin J. Richardson, MD, highlights advances made with CDK4/6 inhibitors in the treatment of patients with hormone receptor-positive metastatic breast cancer and forecasts where treatment is headed in this space.

Dr. Hunt on Treating Local Regional Recurrence in Breast Cancer

March 26th 2019

Kelly Hunt, MD, professor and chair of Breast Surgical Oncology at The University of Texas MD Anderson Cancer Center, discusses treatment approaches for patients with breast cancer who have local regional recurrence.

Using Recurrence Risk to Tailor Treatment in HR+/HER2- Breast Cancer

March 25th 2019

Ruta D. Rao, MD, highlights the importance of determining risk for recurrence and its impact on conversations about extended adjuvant endocrine therapy and the use of chemotherapy in patients with early-stage HR-positive, HER2-negative breast cancer.